Provided by Tiger Trade Technology Pte. Ltd.

Clene Inc

4.71
-0.6800-12.62%
Post-market: 4.750.0400+0.85%19:39 EDT
Volume:176.66K
Turnover:845.51K
Market Cap:55.48M
PE:-1.77
High:5.48
Open:5.31
Low:4.57
Close:5.39
52wk High:13.50
52wk Low:2.28
Shares:11.78M
Float Shares:8.84M
Volume Ratio:2.09
T/O Rate:2.00%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.6548
EPS(LYR):-2.6548
ROE:-1738.36%
ROA:-63.46%
PB:-3.15
PE(LYR):-1.77

Loading ...

JonesTrading Sticks to Their Buy Rating for Clene (CLNN)

TIPRANKS
·
Jan 17

10% Owner Chidozie Ugwumba Reports Sale of Clene Inc. Common Shares

Reuters
·
Jan 17

Clene Inc. to Present Corporate Update at Emerging Growth Conference

Reuters
·
Jan 16

10% Owner Chidozie Ugwumba Reports Disposal of Clene Inc. Common Shares

Reuters
·
Jan 13

Clene Inc. Reports Biomarker Data Linking CNM-Au8 to Reduced ALS Mortality Risk

Reuters
·
Jan 12

Clene Announces Additional Cnm-AU8 Biomarker Data Supporting Potential Nda Filing for Upcoming in-Person FDA Meeting

THOMSON REUTERS
·
Jan 12

BRIEF-Clene Announces Registered Direct Offering Of Over $28 Million

Reuters
·
Jan 09

10% Owner Chidozie Ugwumba Reports Sale of Clene Inc. Common Shares

Reuters
·
Jan 08

10% Owner Chidozie Ugwumba Reports Disposal of Clene Inc. Common Shares

Reuters
·
Dec 31, 2025

10% Owner Chidozie Ugwumba Reports Disposal of Clene Inc. Common Shares

Reuters
·
Dec 24, 2025

Have Insiders Sold Clene Shares Recently?

Simply Wall St.
·
Dec 21, 2025

10% Owner Chidozie Ugwumba Reports Disposal of Clene Inc. Common Shares

Reuters
·
Dec 19, 2025

Clene Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Dec 10, 2025

Clene Inc. to Present Corporate Update at Emerging Growth Conference

Reuters
·
Dec 09, 2025

Clene Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Dec 04, 2025

BRIEF-Clene Announces Statistically Significant ALS Biomarker Results

Reuters
·
Dec 03, 2025

Clene Reports Statistically Significant ALS Biomarker Results for CNM-Au8 Supporting Accelerated FDA Approval Pathway

Reuters
·
Dec 03, 2025

Clene Announces Statistically Significant ALS Biomarker Results Supporting Accelerated Approval Pathway for Cnm-AU8®

THOMSON REUTERS
·
Dec 03, 2025

Clene Inc. Announces CNM-Au8 ALS Program Update Webcast

Reuters
·
Dec 03, 2025

Clene to Provide Cnm-AU8® ALS Program Update

THOMSON REUTERS
·
Dec 03, 2025